ArticleAddiction science & clinical practice2014
A chance to stop and breathe: participants' experiences in the North American Opiate Medication Initiative clinical trial.
Article in Addiction science & clinical practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00175357 (North American Opiate Medication Initiative), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
North American Opiate Medication Initiative (NAOMI): Multi-Centre, Randomized Controlled Trial of Heroin-Assisted Therapy for Treatment-Refractory Injection Opiate Users
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder.Substance abuse treatment, prevention, and policy · 2017Trial
- Gender differences regarding interest in opioid agonist treatment with hydromorphone: a cross-sectional study of syringe service program participants.Harm reduction journal · 2025Article
- Barriers and facilitators to injectable opioid agonist treatment engagement within a structural vulnerability context: a qualitative study of patient experiences in Vancouver, Canada.Harm reduction journal · 2025Article
- Hydromorphone Hopes: A Qualitative Study of People Initiating Supervised Short-Acting Injectable Opioid Treatment in Australia.Drug and alcohol review · 2025Article
- "It's a delicate balance": clinicians' experiences of providing heroin-assisted treatment.Harm reduction journal · 2024Article
- Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities.Harm reduction journal · 2023Article
- Patients' satisfaction with heroin-assisted treatment: a qualitative study.Harm reduction journal · 2023Article
- 'This is hardcore': a qualitative study exploring service users' experiences of Heroin-Assisted Treatment (HAT) in Middlesbrough, England.Harm reduction journal · 2023Article
- "It's Helped Me a Lot, Just Like to Stay Alive": a Qualitative Analysis of Outcomes of a Novel Hydromorphone Tablet Distribution Program in Vancouver, Canada.Journal of urban health : bulletin of the New York Academy of Medicine · 2021Article
- Motivations to initiate injectable hydromorphone and diacetylmorphine treatment: A qualitative study of patient experiences in Vancouver, Canada.The International journal on drug policy · 2020Article
- Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial.Contemporary clinical trials · 2020Article
- Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment.Substance abuse treatment, prevention, and policy · 2020Article
- Article
- Review
- How Drug Control Policy and Practice Undermine Access to Controlled Medicines.Health and human rights · 2017Article
- Advancing patient-centered care for structurally vulnerable drug-using populations: a qualitative study of the perspectives of people who use drugs regarding the potential integration of harm reduction interventions into hospitals.Addiction (Abingdon, England) · 2016Article
- The Role of Gender in Factors Associated With Addiction Treatment Satisfaction Among Long-Term Opioid Users.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundThe North American Opiate Medication Initiative (NAOMI) clinical trial compared the effectiveness of injectable diacetylmorphine (DAM) or hydromorphone (HDM) to oral methadone maintenance treatment (MMT). This study aimed to determine participants' perceptions of treatment delivered in NAOMI.
methodsA qualitative sub-study was conducted with 29 participants (12 female): 18 (62.1%) received injectable DAM or HDM and 11 (37.9%) received MMT. A phenomenological theoretical framework was used. Semi-structured interviews were audio-recorded and transcribed verbatim. A thematic analysis was used over successive phases and was driven by the semantic meanings of the data.
resultsParticipants receiving injectable medications suggested that the supervised delivery model was stringent but provided valuable stability to their lives. Females discussed the adjustment required for the clinical setting, while males focused on the challenging clinic schedule and its impact on employment abilities. Participants receiving MMT described disappointment with being randomized to this treatment; however, positive aspects, including the quick titration time and availability of auxiliary services, were also discussed.
conclusionTreatment with injectable DAM (or HDM) is preferred by participants and considered effective in reducing the burden of opioid dependency. Engaging patients in research regarding their perceptions of treatment provides a comprehensive assessment of treatment needs and barriers. CLINICAL
trial registrationNCT00175357.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.